- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Australian Biosimilar Trade Group Names New Chair
Health care policy expert Jane Halton, AO, PSM, has been picked for her extensive experience in governmental health affairs.
Australia’s Generic Biosimilars Medicines Association (GBMA) has named health policy expert Jane Halton, AO, PSM, to chair the group in its efforts to expand access and affordable care. The GBMA is a trade association of generic and biosimilar medicine suppliers in Australia. Halton replaces Sylvain Vigneault, who has chaired the GBMA for 2 years.
Halton previously served as chair of the Coalition for Epidemic Preparedness Innovations and co-chair of COVAX, the vaccines component of the ACT Accelerator, a global collaboration to speed up the development and production of coronavirus disease 2019 (COVID-19) tests, treatments, and vaccines. She is also a former secretary of the Australian departments of Health and Finance.
In her biography with the Institute for Health Metrics and Evaluation, a global health research center at the University of Washington, Halton is described as having extensive experience with finance, insurance, risk management, information technology, human resources, health and aging, sport, public policy, and international affairs. She is also an adjunct professor at the University of Sydney and the university of Canberra. She has previously served on the executive board of the World Health Organization.
“To return to my domestic health policy roots and lead the GBMA, at such a significantly important time for Australian patients and our vital health care community, is a challenge I am delighted to embrace,” Halton said. “As we look to the arrival of a COVID-19 vaccine for our citizens, we also need to be vigilant that all Australians continue to receive the medicines they need, when they need them.”
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
